47th week of 2012 patent applcation highlights part 37 |
Patent application number | Title | Published |
20120294773 | APPARATUS FOR HYDROPROCESSING HYDROCARBONS - An apparatus and process is disclosed for hydroprocessing hydrocarbon feed in a hydroprocessing unit and hydrotreating a second hydrocarbon. A warm separator sends vaporous hydrotreating effluent to be flashed with liquid hydroprocessing effluent to produce a vapor flash overhead that can be recycled to the hydrotreating unit to provide hydrogen requirements. | 2012-11-22 |
20120294774 | Selective Co Oxidation for Acetylene Converter Feed Co Control - A system and process for acetylene selective hydrogenation of an ethylene rich gas stream. An ethylene rich gas supply comprising at least H | 2012-11-22 |
20120294775 | TAR-FREE GASIFICATION SYSTEM AND PROCESS - A novel tar-free gasification process and system is disclosed that involves the partial combustion of recycled dry solids and the drying of a slurry feedstock comprising carbonaceous material in two separate reactor zones in a two stage gasifier, thereby producing mixture products comprising synthesis gas. The synthesis gas produced from the high temperature first stage reaction zone is then quenched in the second stage reaction zone of the gasifier prior to introduction of a slurry feedstock. The temperature of the final syngas exiting the second stage reaction zone of the gasifier is thereby moderated to be in the range of about 350-900° F., which is below the temperature range at which tar is readily formed, depending upon the type of carbonaceous feedstock utilized. | 2012-11-22 |
20120294776 | Combined Carbon Dioxide and Oxygen Process for Ethylbenzene Dehydrogenation to Styrene - Processes for using a combination of carbon dioxide and oxygen in the dehydrogenation of hydrocarbons are provided. A hydrocarbon feedstock, carbon dioxide and oxygen are fed to an oxidative dehydrogenation reactor system containing one or more catalysts that promote dehydrogenation of the hydrocarbon feedstock to produce a dehydrogenated hydrocarbon product. The processes of the present invention may be used, for example, to produce styrene monomer by dehydrogenation of ethylbenzene using carbon dioxide and oxygen as oxidants. | 2012-11-22 |
20120294777 | EXTRACTION APPARATUS - An extraction apparatus capable of continuously and efficiently extracting a biological substance is provided. Multiple rotation discs are utilized in the extraction apparatus to significantly improve the efficiency of extracting the biological substance by using an extraction solvent. Specifically, when the extraction solvent is applied to extract lipids from microalgae, retention time of the microalgae in the extraction solvent can be significantly increased, and solubility of the microalgal lipids in the extraction solvent can be improved. Hence, the efficiency of extracting the lipids from the microalgae by using the extraction solvent can be enhanced. On the other hand, owing to the improvement of the efficiency of extracting the lipids from the microalgae, the amount of the extraction solvent can be reduced, and production costs can be reduced as well. | 2012-11-22 |
20120294778 | APPARATUS FOR SECURELY PROCESSING BIOLOGICAL SAMPLE - An apparatus for securely processing biological sample is used to wash, separate, or purify biological molecules, such as DNAs, RNAs, and proteins. The apparatus comprises at least one semi-permeable membrane column, a vacuum manifold, and at least one optional adaptor column. The semi-permeable membrane column is loosely received in the slot of the vacuum manifold. When the adaptor column is used, the semi-permeable membrane column is loosely received in the adaptor column, and the adaptor column is loosely received in the slot of the vacuum manifold. The apparatus also comprises sealing elements which are inserted between the column and the slot. When the semi-permeable membrane column contains liquid sample and vacuum is applied to the vacuum manifold, the liquid in the semi-permeable membrane column can be drawn out of the column through the membrane. | 2012-11-22 |
20120294779 | STRUCTURED PACKING FOR A REACTOR - A structured packing for a reactor is formed from a metal sheet to promote heat and mass transfer near the wall of the reactor. The structured packing causes lateral flow of fluids flowing through the packing such that jet impingement of at least one reactor wall is promoted. The packing may be used in a cylindrical, annular or plate-type reactor, e.g., a catalytic reactor, or a heat exchanger. | 2012-11-22 |
20120294780 | DROP-IN NOZZLE - A drop-in nozzle system for use with a multi-well or multi-column synthesizer or other element distribution system. The drop-in nozzle system includes one or more insertable/removable and/or disposable nozzle inserts, a nozzle housing, an input tube and a fitting. The one or more nozzle inserts are able to vary in length and have ferrule assembly positioned at the top of the insert. As a result, the system enables a user to disconnect a fitting from a nozzle housing cavity thereby releasing the system's liquid-tight seal, replace the current nozzle insert with another insert, and then reconnect the fitting recreating the liquid-tight seal and enabling the system for operation with the new nozzle insert. | 2012-11-22 |
20120294781 | Vacuum Base and Related Methods and Apparatus for Vacuum Filtration - Liquid filter assemblies including an upper sample reservoir, a sample filter and a lower storage bottle are supported by a vacuum base. The base has a vacuum inlet port and, for connection to the liquid filter assembly, a vacuum outlet port. A vacuum is provided through the base to below the sample filter to draw sample liquid through the sample filter into the storage bottle. The base may include an auxiliary vacuum outlet port for connection with additional devices. The bases may be connected from one to another through auxiliary vacuum outlets and the vacuum inlets to make a chain of liquid filter assemblies supplied from one vacuum source. Alternatively, one base may include multiple vacuum outlet ports so that it may support and supply vacuum to a plurality of liquid filter assemblies. | 2012-11-22 |
20120294782 | Fixation and storage of biological organic samples - A method for automatically dosing a fixative solution in a flexible bag containing at least one biological organic sample comprises placing the bag with the sample in a dosing system (e.g., on a holder or weighing device), computing a the required volume or weight of fixative solution as a function of the sample or the bag with the sample, and automatically transferring the computed volume or weight of fixative solution from a storage container into the bag. A system is also described for automatically dosing a fixative solution in a flexible bag containing at least one biological organic sample, a carrier for said flexible bags, and a storage cabinet for storing the carrier. | 2012-11-22 |
20120294783 | Integrated Hydrogen Production and Hydrocarbon Extraction - Reformer and method for producing hydrogen and steam where steam is used for steam-assisted extraction of heavy hydrocarbons. Steam is injected into a hydrocarbon-containing reservoir. Hydrocarbons are extracted from the reservoir along with produced water. Hydrogen is produced in a catalytic steam hydrocarbon reformer. Combustion product gas from the reformer is used to generate wet steam in a once-through steam generator from produced water recycled from the reservoir. The wet steam is used for the steam-assisted extraction of heavy hydrocarbons. The reformer has a heat exchanger section where a heat exchanger is suitable for processing the produced water by once-through steam generation and is suitable for mechanical cleaning. | 2012-11-22 |
20120294784 | METHODS AND APPARATUSES FOR PRODUCING STYRENE FROM ETHYLBENZENE - Embodiments of methods and apparatuses for producing styrene are provided. The method comprises the steps of introducing ethylbenzene to a first dehydrogenation reactor containing a first high activity dehydrogenation catalyst at a first predetermined inlet temperature to form a first intermediate effluent stream that comprises styrene, ethylbenzene, and hydrogen. Oxygen is added to the first intermediate effluent stream to form a first oxygenated intermediate effluent stream. The first oxygenated intermediate effluent stream is introduced to a first oxidation-reheat dehydrogenation reactor at a second predetermined inlet temperature of about 530° C. or less to form styrene. The first oxidation-reheat dehydrogenation reactor contains a first oxidation catalyst and a second high activity dehydrogenation catalyst. | 2012-11-22 |
20120294785 | ACIDIC GAS ABSORBENT, ACIDIC GAS REMOVAL DEVICE, AND ACIDIC GAS REMOVAL METHOD - An acidic gas absorbent having a high acidic gas absorption capacity, that is, a high acidic gas absorption amount and a high acidic gas absorption rate, an acidic gas absorption device, and a method for absorbing an acidic gas, are provided. An acidic gas absorbent containing an azabicyclo compound and a primary or secondary amine compound; an acidic gas absorbent containing a heteroaromatic ring compound and a primary or secondary amine compound; an acidic gas removal device using these acidic gas absorbents; and a method for removing an acidic gas are disclosed. | 2012-11-22 |
20120294786 | EXHAUST PURIFICATION DEVICE AND EXHAUST PURIFICATION METHOD FOR DIESEL ENGINE - Provided are an exhaust purification device for a diesel engine, and an exhaust purification method that utilizes this exhaust purification device enabling effective utilization of exhaust gas heat and allowing reduction in the size of the device, by virtue of the design of the layout of each post-processing units. An exhaust purification device | 2012-11-22 |
20120294787 | METHOD FOR REDUCTION OF THE CO2 CONTENT OF FLUE AND ATMOSPHERIC GASES, AND EQUIPMENTS FOR APPLICATION OF THE METHOD - The subject of the invention is a method for reduction of the CO | 2012-11-22 |
20120294788 | Method and apparatus for desalination of water and extraction of carbon dioxide from flue gas via controlled and variable gas atomization - A water-desalination and carbon dioxide extraction method employs a greenhouse having a transparent, double-pane roof structure and containing an open-top receptacle for a receiving quantity of saline water or an aqueous mixture, derived from flue gas, of dissolved and suspended alkaline metal salts, which roof structure and receptacle are substantially coextensive and rectangular. A series of remotely controllable nozzles, capable of producing sheet-like discharges, withdraw the saline water or the aqueous mixture from the receptacle and discharges it into the overlying space for exposure to solar radiation passing through the roof structure, for controlled absorption of solar energy by the saline water or for effecting release carbon dioxide at elevated temperatures. Ambient air, heated during passage through channels in the transparent roof structure, may be used in a second greenhouse for promoting evaporation of free water or in other method steps. | 2012-11-22 |
20120294789 | CO SHIFT CATALYST, CO SHIFT REACTOR, AND METHOD FOR PURIFYING GASIFIED GAS - A CO shift catalyst according to the present invention is one that reforms carbon monoxide (CO) in gas. The CO shift catalyst includes: active ingredients including one of molybdenum (Mo) and iron (Fe) as a main ingredient and one of nickel (Ni) and ruthenium (Ru) as an accessory ingredient; and one or at least two oxides of titanium (Ti), zirconium (Zr), and cerium (Ce) as a carrier supporting the active ingredients. The CO shift catalyst can be used for a CO shift reactor | 2012-11-22 |
20120294790 | SILICON CARBIDE SUBSTRATE, SILICON CARBIDE INGOT, AND METHODS FOR MANUFACTURING SILICON CARBIDE SUBSTRATE AND SILICON CARBIDE INGOT - A method of manufacturing a silicon carbide ingot having highly uniform characteristics includes a preparation step of preparing a base substrate made of single crystal silicon carbide and having an off angle of 0.1° or more and 10° or less in an off angle direction which is either a <11-20> direction or a <1-100> direction relative to a (0001) plane, and a film formation step of growing a silicon carbide layer on a surface of the base substrate. In the film formation step, a region having a (0001) facet | 2012-11-22 |
20120294791 | METHOD OF PRODUCING CYCLOHEXASILANE COMPOUNDS - A method of preparing a cyclohexasilane compound from trichlorosilane is provided. The method includes contacting trichlorosilane with a reagent composition to produce a compound containing a tetradecahalocyclohexasilane dianion, such as a tetradecachlorocyclohexasilane dianion. The reagent composition typically includes (a) tertiary polyamine ligand; and (b) a deprotonating reagent, such as a tertiary amine having a pKa of at least about 10.5. Methods of converting the tetradecahalocyclohexasilane dianion-containing compound to cyclohexasilane or a dodecaorganocyclohexasilane are also provided. | 2012-11-22 |
20120294792 | ZROX, CE-ZROX, CE-ZR-REOX as Host Matrices for Redox Active Cations for Low Temperature, Hydrothermally Durable and Poison Resistant SCR Catalysts - The present invention relates to application of catalysts for the Selective Catalytic Reduction of oxides of Nitrogen using N-containing reductant. The catalysts are characterised as phase pure lattice oxide materials into which catalytically active cations are incorporated at high levels of dispersion such that conventional analysis reveals a highly phase pure material. The materials are further characterised by high activity, hydrothermal durability and poison tolerance in the intended application. | 2012-11-22 |
20120294793 | PRODUCTION OF GRAPHENE SHEETS AND RIBBONS - A method comprises: physically attaching one or more of metals, metal compounds or oxides to walls of carbon nanotubes; treating the metals, metal compounds or oxides to bond the metals, metal compounds, or oxides chemically to the carbon nanotubes; removing the metals, metal compounds or oxides from the walls of the carbon nanotubes resulting in defected carbon nanotubes; and unzipping the defected carbon nanotubes into graphene sheets or ribbons. | 2012-11-22 |
20120294794 | Process for the Production of Chlorine Dioxide - The invention relates to a process for the production of chlorine dioxide comprising formation of an aqueous solution comprising chlorine dioxide, bringing at least part of the aqueous solution comprising chlorine dioxide to its end-application within an average residence time of less than 60 minutes, and maintaining part of the obtained aqueous solution comprising chlorine dioxide in at least one storage tank. | 2012-11-22 |
20120294795 | HYDRAULIC DESALINATION DEVICE AND METHOD - A hydraulic desalination system, device and method includes lowering the pressure of liquid saltwater to the vaporization point by generating flow through piping and accompanying infrastructure that may include valves that impart friction and control flow, capturing the vapor, condensing the vapor using higher pressure supplied by the ambient surroundings producing freshwater, recovering the heat released during condensation by maintaining ambient temperatures greater than vapor temperatures, and then using the recovered heat to enhance and perpetuate vaporization in a cyclical manner. A novel spring-loaded pump for pumping fluids may facilitate the process. | 2012-11-22 |
20120294796 | Antibodies Reactive with B7-H3 and Uses Thereof - The present invention relates to antibodies that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers. | 2012-11-22 |
20120294797 | ANTI-CGRP COMPOSITIONS AND USE THEREOF - The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V | 2012-11-22 |
20120294798 | METHODS OF TREATING CANCER USING IL-21 - Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer therapeutics. | 2012-11-22 |
20120294799 | ANTI-TEM1 ANTIBODIES AND USES THEREOF - The invention relates to Anti-TEM 1 anti-bodies or antigen-binding fragments thereof, yeast libraries comprising the same, and prophylactic, diagnostic, and therapeutic methods using the same. | 2012-11-22 |
20120294800 | TARGETING TUMOR CELLS WITH CHEMOTHERAPEUTIC AGENTS CONJUGATED TO MATRIPTASE ANTIBODIES - The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as doxorubicin (DOX) are introduced, which are equipotent to anticancer agents used in free form but exhibit significantly reduced cardiotoxicity and almost no adverse effects on normal bone marrow-derived mesenchymal stromal cells that do not express matriptase. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase. In addition, administration of a matriptase antibody or immunoconjugates of a matriptase antibody and a cytotoxic agent in combination with administration of an immunomodulatory agent, such as thalidomide or an analog thereof, provides a more effective treatment of these cancers. | 2012-11-22 |
20120294801 | CONJUGATES OF RGD PEPTIDES AND PORPHYRIN OR (BACTERIO)CHLOROPHYLL PHOTOSYNTHESIZERS AND THEIR USES - Conjugates of porphyrin, chlorophyll and bacteriochlorophyll photosensitizers with RGD-containing peptides or RGD peptidomimetics are provided that are useful for photodynamic therapy (PDT), particularly vascular-targeted PDT (VTP), of tumors and nonneoplastic vascular diseases such as age-related macular degeneration, and for diagnosis of tumors by different techniques. | 2012-11-22 |
20120294802 | USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS - The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like. | 2012-11-22 |
20120294803 | CXCR4 ANTAGONISTS FOR IMAGING OF CANCER AND INFLAMMATORY DISORDERS - The invention provides radiolabeled CXCR4 antagonists, compositions and methods of use for imaging of chemokine CXCR4 receptors and biological conditions associated with the expression of CXCR4 receptors, including cancer, metastasis, and inflammatory disorders. | 2012-11-22 |
20120294804 | PHENYLETHANOLAMINE-BASED NMDA RECEPTOR ANTAGONISTS - Described herein are enhanced N-methyl-D-aspartate (NMDA) receptor antagonists, pharmaceutical compositions thereof, and their methods of use and treatment, e.g., of Formula (I): | 2012-11-22 |
20120294805 | DNA regulatory element for the expression of transgenes in neurons of a subject and uses thereof - The present invention provides for a method of evaluating whether a compound is effective in activating a calcium-calmodulin dependent kinase IIα promoter in a human neuronal cell which comprises: (a) contacting the human neuronal cell which has been stably transformed by a recombinant nucleic acid molecule comprising a gene of interest operatively linked to a nucleic acid encoding a calcium-calmodulin dependent kinase IIα promoter which has a nucleotide sequence of the promoter in ATCC Accession No. 98582 with the compound, and (b) comparing the expression level of the gene of interest in the neuronal cell in step (a) with the level in the neuronal cell in the absence of the compound, thereby determining whether the compound is effective in activating the calcium-calmodulin dependent kinase IIα promoter. | 2012-11-22 |
20120294806 | DRUG CARRIER WITH THERMAL SENSITIVITY, MANUFACTURING METHOD THEREOF, AND USE THEREOF - A drug carrier with thermal sensitivity, a manufacturing method thereof, and a use thereof are disclosed. The drug carrier comprises a nano-magnetic particle, a drug, a composite polymer, and a dense silica shell. The nano-magnetic particle and the drug are encapsulated in the composite polymer which is formed by self-assembly a water-soluble polymer (such as poly vinyl alcohol) and a thermosensitive copolymer (such as Pluronic F68 or Pluronic F127). The stability and drug release of the drug carrier a can be adjusted by combining PVA and thermosensitive copolymer with a different ratio. When an external magnetic field was applied, the cores exhibit significant size shrinkage and the diameter of the drug carrier decreases more than 10 folds due to the change of temperature, which causes burst-like drug release because of shell destruction and physical collapse of the drug carrier. | 2012-11-22 |
20120294807 | FLUORESCENT COMPOUNDS - Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided. | 2012-11-22 |
20120294808 | Fluorescent Analogs of Neurotransmitters, Compositions Containing the Same and Methods of Using the Same - A method of imaging using selective fluorescent emitters and compositions for imaging are described. The method can include contacting a specimen with a composition comprising at least one selective fluorescent emitter of Formulas I through IX and irradiating the specimen with an excitation wavelength. The fluorescence emitted by the selective fluorescent emitter can be detected to generate an image. Formulas I through IX are: | 2012-11-22 |
20120294809 | LANTHANOID COMPLEX CAPSULE AND PARTICLE CONTRAST AGENTS, METHODS OF MAKING AND USING THEREOF - The invention relates to compositions of DOTA derivative compounds, lanthanoid-DOTA derivative molecular complex, and lanthanoid-complex encapsulated solid lipid particles or capsules, and methods of making and using the compositions. The solid lipid particles or capsules contain micelle cores stabilized by a hyperbranched polymer shell based from a crosslinked DOTA derivative compound or crosslinked lanthanoid-DOTA derivative complex. These solid lipid particles or capsules can be used in various applications, such as contrast agents or drug delivery vehicles. | 2012-11-22 |
20120294810 | PLACENTAL TISSUE GRAFTS AND IMPROVED METHODS OF PREPARING AND USING THE SAME - A method for preparing placenta membrane tissue grafts for medical use, includes obtaining a placenta from a subject, cleaning the placenta, separating the chorion tissue from the amniotic membrane, mounting a selected layer of either the chorion tissue or the amniotic membrane onto a drying fixture, dehydrating the selected layer on the drying fixture, and cutting the selected layer into a plurality of tissue grafts. Preferably, the drying fixture includes grooves or raised edges that define the outer contours of each desired tissue graft, after they are cut, and further includes raised or indented logos that emboss the middle area of the tissue grafts during dehydration and that enables an end user to distinguish the top from the bottom side of the graft. The grafts are comprised of single layers of amnion or chorion, multiple layers of amnion or chorion, or multiple layers of a combination of amnion and chorion. | 2012-11-22 |
20120294811 | PLACENTAL TISSUE GRAFTS AND IMPROVED METHODS OF PREPARING AND USING THE SAME - A method for preparing placenta membrane tissue grafts for medical use, includes obtaining a placenta from a subject, cleaning the placenta, separating the chorion tissue from the amniotic membrane, mounting a selected layer of either the chorion tissue or the amniotic membrane onto a drying fixture, dehydrating the selected layer on the drying fixture, and cutting the selected layer into a plurality of tissue grafts. Preferably, the drying fixture includes grooves or raised edges that define the outer contours of each desired tissue graft, after they are cut, and further includes raised or indented logos that emboss the middle area of the tissue grafts during dehydration and that enables an end user to distinguish the top from the bottom side of the graft. The grafts are comprised of single layers of amnion or chorion, multiple layers of amnion or chorion, or multiple layers of a combination of amnion and chorion. | 2012-11-22 |
20120294812 | ORAL CARE COMPOSITIONS - Disclosed herein are methods of enhancing the solubility and delivery of one or more active ingredients found in magnolia extract, or a synthetic analogue thereof, in an oral composition. | 2012-11-22 |
20120294813 | Functional branched polyether copolymers and method for the production thereof - The invention relates to highly functional, aliphatic, branched polyethers produced from oxiranes, in particular ethylene oxide and glycidol or the sulfur- or nitrogen-containing analogues thereof. The branched polyethers are in particular suited as a matrix for pharmacological and cosmetic active agents. | 2012-11-22 |
20120294814 | SKIN MOISTURIZER AND AGE FIGHTING FORMULA - Disclosed is a non-ionic oil-in water emulsion comprising less than 50% by weight of water, a combination of non-ionic emulsifiers and non-ionic emulsion stabilizers, a combination of humectant skin conditioning agents, and a combination of UV absorbing agents. The emulsion can be stable and have an SPF of at least 30. | 2012-11-22 |
20120294815 | COSMETIC COMPOSITIONS HAVING LONG LASTING SHINE - The invention relates to a cosmetic composition comprising at least one polyester that may be obtained by reacting:
| 2012-11-22 |
20120294816 | COSMETIC COMPOSITIONS HAVING HIGH SHINE - The invention relates to a cosmetic composition comprising at least one polyester that may be obtained by reacting:
| 2012-11-22 |
20120294817 | COSMETIC COMPOSITIONS HAVING LONG LASTING SHINE - The invention relates to a cosmetic composition comprising at least one polyester that may be obtained by reacting:
| 2012-11-22 |
20120294818 | Antiperspirant Compositions - Compositions containing a relatively high concentration of electrolytes and a thickening agent, wherein the thickening agent comprises a strongly swellable, lightly to moderately crosslinked polyvinyl pyrrolidone. The polyvinyl pyrrolidone thickening agent is characterized by an aqueous gel volume of about 15 to 150 ml/g and a Brookfield viscosity of at least 10,000 cps for a 5% aqueous solution at 25° C. | 2012-11-22 |
20120294819 | NOVEL POLYSILOXANES HAVING QUATERNARY AMMONIUM GROUPS, METHOD FOR PRODUCING SAME AND USE THEREOF IN FORMULATIONS FOR CLEANSING AND CARE - The invention relates to novel polysiloxanes having quaternary ammonium groups, and to a method for producing same. The invention further relates to the use of said polymers as an active care ingredient in formulations for the care and cleansing of skin and skin appendages, for example, as conditioning agents for hair. | 2012-11-22 |
20120294820 | CLEAR, WASHABLE LUBRICANT COMPOSITIONS AND METHODS OF MAKING SAME - Bi- or multiphasic, clear or translucent silicone-containing lubricant compositions, and products including such compositions and methods of making such compositions and products are disclosed. The refractive index of each immiscible phase of the lubricant composition is matched to that of each other phase to make the composition clear or translucent. The compositions are highly lubricious, non-staining, and easily washable. | 2012-11-22 |
20120294821 | Low Volatile Reactive Malodor Counteractives and Methods of Use Thereof - The present invention is a compound for counteracting thiol- and amine-based malodors in consumer, industrial and textile products. | 2012-11-22 |
20120294822 | USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO TREAT DIARRHEA IN SUBJECTS WITH DISEASES OR TREATMENTS THAT RESULT IN ELEVATED CGRP LEVELS - The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof. | 2012-11-22 |
20120294823 | Method for preparing silk sericin-PVA scaffold using genipin as crosslinking agent - A method for preparing a porous-three-dimensional scaffold good for tissue engineering is described. Sericin forms a three-dimensional scaffold with PVA after freeze-drying having glycerin as a plasticizer and genipin as natural crosslinking agent to help making a strong and stable matrix. Adding glycerin into scaffold gives good uniformity and porosity. Smaller pore sizes and better uniformity are obtained as the concentration of genipin in the scaffold increases. Glycerin retains a high moisture content to allow the presence of water molecule in the matrix structure. Adding genipin results in a higher degree of crosslinking within the scaffold. Crosslinking using genipin is most beneficial in preparing scaffold possesses the best biological and physical properties for wound healing. The present invention describes method for preparing crosslinked matrix whose composition can be appropriately tuned to obtain matrix with desirable characteristics for biological applications. | 2012-11-22 |
20120294824 | METHOD FOR PRODUCING ANTIFOULING COATING RESIN DISPERSION - It is an object of the present invention to provide an antifouling coating resin dispersion which has excellent storage stability and water resistance in sea water, can exhibit an antifouling effect over a long period of time, and has self-polishing properties with excellent adhesiveness. A method for producing the antifouling coating resin dispersion according to the present invention includes the steps of: producing a polymer (A) containing a divalent metal; and dispersing the polymer (A) in a dispersion medium containing water or a mixture of water and an organic solvent. The polymer (A) containing a divalent metal is obtained by subjecting 1 to 40% by mass of a divalent-metal-containing ethylenically unsaturated monomer (a1), 0 to 8% by mass of a carboxyl-group-containing ethylenically unsaturated monomer (a2), 0 to 40% by mass of a hydroxyl-group-containing ethylenically unsaturated monomer (a3), and 99 to 22% by mass of another ethylenically unsaturated monomer (a4) to solution polymerization in a multi-stage which includes two or more stages. | 2012-11-22 |
20120294825 | METHOD OF FORMING ANTIFOULING COATING FILM - Provided is a method of forming an antifouling coating film including the steps of [1] preparing a colored antifouling paint containing a prescribed Si-containing hydrolyzable resin and a color pigment such that a coating film having a target dry film thickness T completely hides a surface of an object to be coated, the colored antifouling paint has a color difference ΔE1 between the coating film having the thickness T and a coating film having a dry film thickness of 0.8 T, at least 2.0, and preferably the colored antifouling paint has a color difference ΔE2 between the coating film having the thickness T and a coating film having a dry film thickness of 1.2 T, less than 1, and [2] coating a surface of the object with the colored antifouling paint until the surface of the object is completely hidden by the coating film formed from the colored antifouling paint. | 2012-11-22 |
20120294826 | METHODS, KITS AND COMPOSITIONS FOR AMELIORATING ADVERSE EFFECTS ASSOCIATED WITH TRANSFUSION OF AGED RED BLOOD CELLS - The present invention provides, inter alia, methods for ameliorating an adverse effect in a patient caused by an acute transfusion into the patient of a composition containing aged red blood cells using an iron chelator. Apparatuses and kits for ameliorating such adverse effects are also provided. | 2012-11-22 |
20120294827 | POLYMER GEL FORMULATION - A polymer gel, in at least some embodiments, featuring both cross-linked castor oil and branched castor oil components, in which the castor oil is optionally replaced by ricinoleic acid. | 2012-11-22 |
20120294828 | MURGANTIOL AS AN INDOOR STINK BUG ATTRACTANT - Provided herein are uses of murgantiol for attracting stink bugs in indoor settings. Stink bug traps comprising murgantiol and methods of using murgantiol in traps indoors are provided. Compositions comprising murgantiol are also described. | 2012-11-22 |
20120294829 | LIQUID FORMULATIONS FOR LONG-ACTING G-CSF CONJUGATE - Disclosed is a liquid formulation which allows long-acting G-CSF conjugates, that have improved in vivo duration and stability, to be stable when stored for a long period of time. It comprises a stabilizer composition characterized by buffer and mannitol. Being free of human serum albumin and other potential factors harmful to the body, the liquid formulation is free of concerns about viral infections and guarantees excellent storage stability to long-acting G-CSF conjugates. | 2012-11-22 |
20120294830 | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases - The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity. | 2012-11-22 |
20120294831 | USE OF THIAZOLIDE COMPOUNDS FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES, CANCER AND DISEASES CAUSED BY INTRACELLULAR INFECTIONS - The invention provides for the use of pharmaceutical compositions comprising a thiazolide in the stimulation of the immune system in a subject in need thereof, thereby preventing and/or treating viral diseases, cancer and diseases caused by intracellular protozoan infections | 2012-11-22 |
20120294832 | COMPOSITION COMPRISING INTERFERON ALPHA - The present invention relates to a novel solid composition, useful for treating hepatitis, in particular hepatitis C, comprising at least one interferon alpha and at least one grafted poly(glutamic acid) having an average molar mass ranging from 26,000 to 40,000 g/mol, preferably approximately 33,000 g/mol and carrying grafts of alpha-tocopherol at an average molar grafting rate ranging from 4.5 to 5.5%, preferably approximately 5%, the interferon alpha and said grafted poly(glutamic acid) being present in a grafted poly(glutamic acid)/interferon alpha weight ratio ranging from 21 to 125. | 2012-11-22 |
20120294833 | STRAINS OF LACTIC ACID BACTERIA FOR PREVENTING NECROTIZING ENTEROCOLITIS - The present invention relates to novel strains of lactic acid bacteria, | 2012-11-22 |
20120294834 | REGENERATION OF, REESTABLISHING FUNCTION IN AND REPLACING MICROVASCULATURE IN ORGANS AND TISSUES - The invention provides compositions and methods involving the use of endothelial progenitor cells (EPC) to re-generate and/or reestablish a functioning microvasculature in damaged or ischemic organs and tissue. The invention also provides compositions and methods using EPC for replacing lost function in organ and tissue that is damaged, ischemic, or scarred. Such compositions and methods may find utility in, for instance, organs or tissues that have been damaged due to lack of vasculature. | 2012-11-22 |
20120294835 | SUBSTITUTED PYRIDINES AND PYRIMIDINES - Provided is a compound of formula (I), and/or salt thereof, | 2012-11-22 |
20120294836 | HIGH YIELD METHOD AND APPARATUS FOR VOLUME REDUCTION AND WASHING OF THERAPEUTIC CELLS USING TANGENTIAL FLOW FILTRATION - The present invention provides processes for aseptically processing live mammalian cells in an aqueous medium to produce a cell suspension having a cell density of at least about 10 million cells/mL and cell viability of at least about 90%. These methods comprise a step of reducing the volume of the medium using a tangential flow filter (TFF) having a pore size of greater than 0.1 micron, during which step the trans-membrane pressure (TMP) is maintained at less than about 3 psi and the shear rate is maintained at less than about 4000 sec | 2012-11-22 |
20120294837 | METHODS OF ISOLATING AND CULTURING MESENCHYMAL STEM CELLS - Provided herein is a relatively pure population of mesenchymal stem cells (MSCs) expressing the Notch 2 receptor (Notch 2+ a MSCs). Also provided is a method of isolating from a subject a population of Notch 2+ MSCs and a method of culturing the population of Notch 2+ MSCs. Also provided is a method of treating a subject with a disorder associated with a deficiency or defect in cells of mesenchymal lineage comprising administering a population of Notch 2+ MSCs to the subject. | 2012-11-22 |
20120294838 | Regulation of endogenous gene expression in cells using zinc finger proteins - The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins. | 2012-11-22 |
20120294839 | Prosthetic Apparatus - Prosthetic apparatuses with probiotic microorganisms to control colonization of pathogenic bacteria are disclosed. The prosthetic apparatus may include a first portion having a first mating surface, a second portion having a second mating surface that conforms to the first mating surface, and at least one strain of probiotic microorganisms retained between the first and second mating surfaces prior to implantation of the prosthetic apparatus. | 2012-11-22 |
20120294840 | Use Of Purified 2'-Fucosyllactose, 3-Fucosyllactose and Lactodifucotetraose as Prebiotics - The invention provides compositions and methods for utilizing synthetic human milk oligosaccharides as prebiotics. | 2012-11-22 |
20120294841 | PROBIOTIC MICROORGANISMS AS ACTIVE AGENTS AGAINST CHANGES IN THE SKIN'S MICRORELIEF - The invention relates to the use of at least one probiotic microorganism as an active agent for preventing and/or treating impairments of the skin's microrelief. | 2012-11-22 |
20120294842 | Platelet Additive Solution Having a Sialidase Inhibitor - The present invention relates to a platelet additive solution (PAS) having an amount of one or more sialidase inhibitors and optionally one or more glycan-modifying agents; and one or more of PAS components that includes a salt, a citrate source, a carbon source, and any combination thereof. | 2012-11-22 |
20120294843 | CASPASE INHIBITORS - A compound, or a pharmaceutically acceptable salt or ester thereof, of formula I: | 2012-11-22 |
20120294844 | Methods And Kits For Topical Application, Removal, And Inactivation Of Therapeutic Or Cosmetic Toxin Compositions - This invention relates to methods and kits for safely removing and inactivating topical therapeutic or cosmetic compositions. The methods and kits according to the invention are particularly well suited for removing and inactivating highly toxic substances. | 2012-11-22 |
20120294845 | METHOD OF MAKING A POLYMER PREFERABLY AN (ALKYL) ACRYLOYL POLYCARBONATE, THE POLYMER AND (ALKYL) ACRYLOYL POLYCARBONATE OBTAINED, AND A BIODEVICE COMPRISING SAME - The invention relates to a method for making a polymer wherein during the polymerisation is incorporated in the polymer chain by ring opening polymerisation a cyclic (alkyl)acryloyl carbonate having the formula (4): wherein R | 2012-11-22 |
20120294846 | Treatment of Pulmonary and Pleural Fibrosis Using HSP27 Inhibitors - Reduction of HSP27 expression is in beneficial in the treatment of pleural and pulmonary fibrosis and in particular subpleural fibrosis and IPF. Pharmaceutical compositions for this purpose contain an inhibitor of HSP27 and a pharmaceutically acceptable carrier. | 2012-11-22 |
20120294847 | IMMUNOGLOBULIN REDUCED IN THROMBOGENIC AGENTS AND PREPARATION THEREOF - The invention relates to an immunoglobulin composition reduced in thrombogenic agents and to methods for its preparation. One method comprises subjecting an immunoglobulin containing solution to a negative cation exchanger chromatography at a pH in the range of higher than 3.8 to equal to or lower than 5.3. The solution can also be subjected to a negative anion exchanger chromatography at a pH in the range of 7 to 8.2. | 2012-11-22 |
20120294848 | IGE CH3 Peptide Vaccine - The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine. | 2012-11-22 |
20120294849 | USE OF WF10 FOR TREATING ALLERGIC ASTHMA, ALLERGIC RHINITIS AND ATOPIC DERMATITIS - The present invention provides a method of treating or inhibiting at least one of allergic asthma, allergic rhinitis and atopic dermatitis, or of reducing, inhibiting or treating allergy like symptoms. The methods use compositions comprising chlorite, chloride, chlorate and/or sulfate ions. | 2012-11-22 |
20120294850 | Ganglioside Epitopes For Treating Guillain-Barre Syndrome - Disclosed are compositions and methods for treating Guillain-Barré syndrome (GBS) in a subject that involves neutralizing specific pathogenic anti-glycolipid antibodies in the circulation of the subject. This can involve administering to the subject a molecular mimic of a ganglioside that serves as a specific competitive inhibitor for anti-ganglioside antibodies in the circulation. Also disclosed is an animal model of GBS having anti-ganglioside antibodies in the circulation. | 2012-11-22 |
20120294851 | Cancer Therapies and Pharmaceutical Compositions Used Therein - The invention relates to compositions and methods to inhibit gene expression. In particular, the invention provides co-therapies comprising oligonucleotides plus other therapies to treat cancer. | 2012-11-22 |
20120294852 | ANTAGONISTS OF IL-6 TO RAISE ALBUMIN AND/OR LOWER CRP - The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved. | 2012-11-22 |
20120294853 | CD19 Binding Agents and Uses Thereof - This invention, inter alia, relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease. | 2012-11-22 |
20120294854 | AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS - The present disclosure relates to compounds of formula (I): | 2012-11-22 |
20120294855 | GLP-1 RECEPTOR AGONIST COMPOUNDS FOR OBSTRUCTIVE SLEEP APNEA - The disclosure provides, among other things, the use of GLP-1 receptor agonist compounds to treat obstructive sleep apnea. The GLP-1 receptor agonist compounds may be exendins, exendin analogs, GLP-1(7-37), GLP-1 (7-37) analogs (e.g., GLP-1 (7-36)-NH2) and th like. The GLP-1 receptor agonist compound may be exenatide. | 2012-11-22 |
20120294856 | COMPOUNDS INHIBITING CD95 SIGNALING FOR THE TREATMENT OF PANCREATIC CANCER - The present invention is concerned with compounds inhibiting CD95 signaling in pancreatic cancer cells. Furthermore, contemplated by the current invention are medicaments comprising such a compound for the prevention and/or treatment of pancreatic cancer as well as the use of such a compound for the manufacture of a medicament for the prevention and/or treatment of pancreatic cancer, the prevention of migration of cancer cells, and/or the prevention and/or treatment of an inflammatory reaction. The present invention also refers to a method for the identification of a compound inhibiting CD95 signaling, as we to a method for the manufacture of a medicament comprising the steps of the method for the identification of a compound inhibiting CD95 signaling and the further step of formulating the inhibiting compound as a medicament. | 2012-11-22 |
20120294857 | Monomeric Bi-Specific Fusion Protein - The present invention embraces a bi-specific fusion protein composed of an effector cell-specific antibody-variable region fragment operably linked to at least a portion of a natural killer cell receptor. Methods for using the fusion protein in the treatment of cancer and pathogenic infections are also provided. | 2012-11-22 |
20120294858 | USE OF LONG-ACTING RECOMBINANT HUMAN SOLUBLE TUMOR NECROSIS FACTOR ALPHA RECEPTOR IN MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT AND/OR PROPHYLAXIS OF HEPATIC FAILURE - The present invention belongs to the field of the application of genetic engineering and gene function, and it is directed to a new medical use of the gene encoding the recombinant soluble tumor necrosis factor α receptor (HusTNFR). The present invention made intervention to fulminant hepatic failure in mice by use of the long-acting recombinant human soluble tumor necrosis factor α receptor and the classic animal models of acute and sub-acute hepatic failure. The results showed that the long-acting soluble tumor necrosis factor α receptor of the present invention has a half-life extended more than 10 times, and it significantly decreased the mortality of model animals and has superior therapeutic effect for the treatment and/or prophylaxis of acute and sub-acute hepatic failure in model animals. These receptors have a noticeable therapeutic effect for the treatment and/or prophylaxis of acute and sub-acute hepatic failure in comparison with the non-long-acting HusTNFR. | 2012-11-22 |
20120294859 | CANCER STEM CELL MARKERS AND USES THEREOF - The present invention inter alia pertains to therapeutic methods which are based on the use of an agent specifically binding a tumor-associated carbohydrate antigen for the treatment of cancer stem cells and related diseases. Also provided are diagnostic and prognostic methods using a tumor-associated carbohydrate antigen as marker for cancer stem cells. | 2012-11-22 |
20120294860 | MEDICAMENT FOR TREATING AND/OR PREVENTING CANCER - This invention relates to a medicament for treating and/or preventing a cancer, comprising a combination of an antibody against a cancer antigen CAPRIN-1 protein that is specifically expressed on the surface of the cancer cell, and an antitumor agent, wherein the antibody and the antitumor agent are combined together or separately, and to a use of the medicament. | 2012-11-22 |
20120294861 | FGFR1 AGONISTS AND METHODS OF USE - The invention provides FGFR1 agonists, including agonistic anti-FGFR1 antibodies, and methods of using the same. | 2012-11-22 |
20120294862 | ANTAGONISTS OF IL-17A, IL-17F, AND IL-23P19 - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease. | 2012-11-22 |
20120294863 | Anti-CD70 Antibody and Its Use for the Treatment and Prevention of Cancer and Immune Disorders - Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunomodulatory without conjugation to a therapeutic agents as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering the CD70 binding agents to a subject. | 2012-11-22 |
20120294864 | Endoglin Antibodies - The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof. | 2012-11-22 |
20120294865 | Integrin Alpha-2 Binding Agents and Use Thereof to Inhibit Cancer Cell Proliferation - The invention provides an integrin alpha-2 binding agent and methods of using an integrin alpha-2 binding agent to, e.g., inhibit proliferation of cancer cells, modulate tumor growth in a subject, inhibiting angiogenesis, or treating a fibrotic disorder. The invention further provides a method of producing an antibody, the method comprising propagating cancer cells in a 3-dimensional matrix; immunizing a mammal with the propagated cancer cells; and isolating an antibody from the immunized mammal. A method of identifying an agent that inhibits cancer cell proliferation also is provided. | 2012-11-22 |
20120294866 | PHARMACEUTICAL FORMULATION FOR PROTEINS - The present invention provides a liquid pharmaceutical formulation comprising a therapeutic protein, a surfactant and at least an antioxidant selected from the group of radical scavengers, chelating agents or chain terminators. | 2012-11-22 |
20120294867 | METHOD FOR EGFR DIRECTED COMBINATION TREATMENT OF CANCER - The present invention relates to a method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR), wherein an irreversible tyrosine kinase inhibitor (TKI) is administered according to a continuous regimen based on an average daily dose in the range of 10 to 50 mg and the mAB is co-administered according to a dosing regimen ranging from an average weekly iv dose of 50 to 500 mg/m | 2012-11-22 |
20120294868 | ANTI-TGF-BETA INDUCTION OF BONE CELL FUNCTION AND BONE GROWTH - The invention regards the modulation of TGF-β activity by administering to a subject an antibody that binds to TGF-β, thereby increasing bone growth, bone formation, bone mass and bone strength. The antibody acts to increase osteoblast number and function while at the same time decreasing osteoclast number and function. Such drugs are useful in the treatment of diseases or disorders such as osteoporosis, Paget's disease, metastatic bone cancer, myeloma bone disease, bone fractures, etc. | 2012-11-22 |
20120294869 | Methods for Treating Fatty Liver Disease - The present invention relates to the compositions, formulations and methods of treating fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and their sequelae by administration of uridine or a compound that modulates one or more uridine phosphorylases in a subject in need thereof. | 2012-11-22 |
20120294870 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS - Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating a tumor include administration of an agent that reduces cellular invasion resulting from the interaction between a fragment of OPN (OPN-5kD) generated by MMP-9 cleavage and CD44 receptor. Examples of such agents include fragments of OPN-5kD and antibodies specific for OPN-5kD. Therapeutic compositions are also provided that include such agents. Also provided are methods of diagnosing or prognosing a tumor, for example by detecting expression of OPN-5kD peptide or OPN-c mRNA in a biological sample obtained from the subject. Also provided are antibodies that specifically bind OPN-5kD. | 2012-11-22 |
20120294871 | MODULATION OF GPCR-MEDIATED CAMP PRODUCTION THROUGH LRP6 AND ITS THERAPEUTIC APPLICATION - The present invention relates to low-density lipoprotein receptor related protein 6 (LRP6). More specifically, the present invention relates to targeting of LRP6 to modulate Gα | 2012-11-22 |
20120294872 | Method of Predicting and Reducing Risk of Metastasis of Breast Cancer to Lung - A signature for breast cancer tissue derived from a patient is established that is indicative of the virulence and risk of lung metastasis by determining the expression levels to define a sample signature, and comparing this sample signature to a reference signature. This determination is used to define appropriate treatment and monitoring options for the patient. Risk of metastasis to the lung can be reduced by treatment with a therapeutic combination that either (1) contains a first agent effective to inhibit epiregulin activity and a second agent effective to inhibit activity of a protein selected from the group consisting of MMP1, MMP2 and PTGS2, or (2) contains a therapeutic agent or combination of agents effective to inhibit activity MMP1, MMP2 and PTGS2. Agents that inhibit the CXCL1 pathway also can be used individually or in combination with these combinations. | 2012-11-22 |